| Literature DB >> 34822500 |
Jianing Chen1, Lin Xu1, Yanrong Zhou1, Bingnan Han1.
Abstract
The actinomycetes have proven to be a rich source of bioactive secondary metabolites and play a critical role in the development of pharmaceutical researches. With interactions of host organisms and having special ecological status, the actinomycetes associated with marine animals, marine plants, macroalgae, cyanobacteria, and lichens have more potential to produce active metabolites acting as chemical defenses to protect the host from predators as well as microbial infection. This review focuses on 536 secondary metabolites (SMs) from actinomycetes associated with these marine organisms covering the literature to mid-2021, which will highlight the taxonomic diversity of actinomycetes and the structural classes, biological activities of SMs. Among all the actinomycetes listed, members of Streptomyces (68%), Micromonospora (6%), and Nocardiopsis (3%) are dominant producers of secondary metabolites. Additionally, alkaloids (37%), polyketides (33%), and peptides (15%) comprise the largest proportion of natural products with mostly antimicrobial activity and cytotoxicity. Furthermore, the data analysis and clinical information of SMs have been summarized in this article, suggesting that some of these actinomycetes with multiple host organisms deserve more attention to their special ecological status and genetic factors.Entities:
Keywords: actinomycetes; biological activities; macroalgae; marine animals; marine plants; secondary metabolites; structural diversity
Mesh:
Substances:
Year: 2021 PMID: 34822500 PMCID: PMC8621598 DOI: 10.3390/md19110629
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Neighbor-Joining phylogenetic tree based on 16S rRNA gene sequences of natural product-producing actinomycetes. The aligned sequences were analyzed by the bootstrap method with a bootstrap number of 10,000. The colored labels indicate the classification of actinomycetes; the outer color strip shows their host sources.
Figure 2Structures of compounds 1–78.
Figure 3Structures of compounds 79–84.
Figure 4Structures of compounds 85–100.
Figure 5Structures of compounds 101–123.
Figure 6Structures of compounds 124–166.
Figure 7Structures of compounds 167–176.
Figure 8Structures of compounds 177–199.
Figure 9Structures of compounds 200–205, 301.
Figure 10Structures of compounds 206–222.
Figure 11Structures of compounds 223–226.
Figure 12Structures of compounds 227–258.
Figure 13Structures of compounds 259–262.
Figure 14Structures of compounds 263–265.
Figure 15Structures of compounds 266–274.
Figure 16Structures of compounds 275–280.
Figure 17Structures of compounds 281–285.
Figure 18Structures of compounds 286–300, 302–305.
Figure 19Structures of compounds 306–331.
Figure 20Structures of compounds 332–340.
Figure 21The structural distribution of metabolites from the actinomycetes is divided by genera.
Figure 22The structural distribution of metabolites from -actinomycetes associated with various hosts. The dots in that figure represent the number of compounds and the color darkens when the dots overlap.
Figure 23The distribution of secondary metabolites produced by actinomycetes with various genera derived from different hosts. The width of the extended branches in the figure corresponds to the number of secondary metabolites.
Figure 24The structural distribution of metabolites from three dominant actinomycetes in the main host’s sponge and ascidian. The x-axis labels represent the host-genus-structure classes of actinomycetes: (A) Ascidian; (S) Sponge; (Str) Streptomyces; (Mic) Micromonospora; (Sac) Saccharopolyspora; (Act) Actinomadura; (al) alkaloid; (po) polyketide.
Figure 25The diversity distribution of biological activity with different structures.
Clinical information of the secondary metabolites.
| Compounds | Study Title | Conditions | Related Compounds for Interventions | Phase | NCT Number |
|---|---|---|---|---|---|
| Rifamycin SV ( | Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis | Uncomplicated Diverticulitis | Rifamycin SV-MMX® | Phase 2 | NCT01847664 |
| Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D | Diarrhea-predominant Irritable Bowel Syndrome | Rifamycin SV | Phase 2 | NCT03099785 | |
| Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler’s Diarrhea (TD) | Traveler’s Diarrhea | Rifamycin SV MMX | Phase 3 | NCT01142089 | |
| Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller’s Diarrhoea | Traveler’s Diarrhea | Rifamycin SV-MMX® | Phase 3 | NCT01208922 | |
| Diazepinomicin ( | A Phase I Study of ECO-4601 in Patients With Advanced Cancer | Tumors | ECO-4601 | Phase 1 | NCT00338026 |
| Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme | Glioblastoma Multiforme | TLN-4601 | Phase 2 | NCT00730262 | |
| Staurosporine ( | A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms | Breast Cancer | 7-hydroxystaurosporine (UCN-01) | Phase 1 | NCT00001444 |
| PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function | Hepatic Impairment | Midostaurin | Phase 1 | NCT01429337 | |
| Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia | Midostaurin | Phase 1 | NCT01174888 | |
| Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia | Midostaurin | Phase 2 | NCT03092674 | |
| Tetrodotoxin ( | Tetrodotoxin Open-label Efficacy and Safety Continuation Study | Pain | Tetrodotoxin | Phase 3 | NCT00726011 |
| Safety & Efficacy Study of Subcutaneous Tetrodotoxin for Moderate to Severe Inadequately Controlled Cancer-related Pain | Pain | Tetrodotoxin | Phase 3 | NCT00725114 | |
| Daunomycin ( | Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients | Acute Myeloid Leukemia (AML) | Daunorubicin | Phase 2 | NCT01999413 |
| A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50–70 Years Old | Acute Myeloid Leukemia | Daunorubicin | Phase 3 | NCT00927498 | |
| Linoleic acid ( | Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue | Breast Cancer | Conjugated Linoleic Acid (CLA) | Early Phase 1 | NCT00908791 |
| Conjugated Linoleic Acid / Leucine Versus Metformin on Visceral Fat in Metabolic Syndrome | Metabolic Syndrome | Conjugated linoleic acid/Leucine | Phase 2 | NCT02629627 | |
| Conjugated Linoleic Acid and Atherosclerosis | Atherosclerosis | Cis9, trans11 conjugated linoleic acid | Phase 3 | NCT00706745 | |
| Actinomycin D ( | Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia | Gestational Trophoblastic Tumor | Dactinomycin | Phase 2 | NCT00003688 |
| Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity | Melanoma | Dactinomycin | Phase 2 | NCT01323517 | |
| Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia | Gestational Trophoblastic Neoplasia | Dactinomycin | Phase 3 | NCT00003702 |